EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐ NIT )

Takuya Fujimoto, Osamu Yamasaki, Noriyuki Kanehira, Hirokazu Matsushita, Yoshinori Sakurai, Naoya Kenmotsu, Ryo Mizuta, Natsuko Kondo iD, Takushi Takata, Mizuki Kitamatsu, Kazuyo Igawa, Atsushi Fujimura iD und 8 weitere

Cancer Science · 2024-10 · 115 (10) · 3231-3247

DOI: 10.1111/cas.16298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 09.08.2024. Verfasst von Takuya Fujimoto und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Melanoma, Experimental, CD8-Positive T-Lymphocytes, Immunotherapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are effective against many advanced malignancies. However, many patients are nonresponders to immunotherapy, and overcoming this resistance to treatment is important. Boron neutron capture therapy (BNCT) is a local chemoradiation therapy with the combination of boron drugs that accumulate selectively in cancer and the neutron irradiation of the cancer site. Here, we report the first boron neutron immunotherapy (B‐NIT), combining BNCT and ICI immunotherapy, which was performed on a radioresistant and immunotherapy‐resistant advanced‐stage B16F10 melanoma mouse model. The BNCT group showed localized tumor suppression, but the anti‐PD‐1 antibody immunotherapy group did not show tumor suppression. Only the B‐NIT group showed strong tumor growth inhibition at both BNCT‐treated and shielded distant sites. Intratumoral CD8+ T‐cell infiltration and serum high mobility group box 1 (HMGB1) levels were higher in the B‐NIT group. Analysis of CD8 + T cells in tumor‐infiltrating lymphocytes (TILs) showed that CD62L‐ CD44 + effector memory T cells and CD69 + early‐activated T cells were predominantly increased in the B‐NIT group. Administration of CD8‐depleting mAb to the B‐NIT group completely suppressed the augmented therapeutic effects. This indicated that B‐NIT has a potent immune‐induced abscopal effect, directly destroying tumors with BNCT, inducing antigen‐spreading effects, and protecting normal tissue. B‐NIT, immunotherapy combined with BNCT, is the first treatment to overcome immunotherapy resistance in malignant melanoma. In the future, as its therapeutic efficacy is demonstrated not only in melanoma but also in other immunotherapy‐resistant malignancies, B‐NIT can become a new treatment candidate for advanced‐stage cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron Neutron Capture TherapyMelanoma, ExperimentalCD8-Positive T-LymphocytesImmunotherapyImmune Checkpoint InhibitorsAnimalsMiceFemaleMice, Inbred C57BLLymphocytes, Tumor-InfiltratingCell Line, TumorDrug Resistance, NeoplasmCombined Modality TherapyHMGB1 Protein

Stichwörter der Autor:innen

abscopal effectadvanced melanomaboron neutron capture therapyboron‐neutron immunotherapyimmune combination therapy

Substanzen

Immune Checkpoint InhibitorsHMGB1 Protein

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Neutron Therapy Research Center, Okayama University, Okayama, Japan.
  • Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan.
  • Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Institute for Integrated Radiation and Nuclear Science, Kyoto University, Sennan-gun, Japan.

ORCID-Profile: Natsuko Kondo, Atsushi Fujimura, Yosuke Togashi, Toshiyoshi Fujiwara, Hiroyuki Michiue

Förderung

  • Takeda Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Fujimoto, T., Yamasaki, O., Kanehira, N., Matsushita, H., Sakurai, Y., Kenmotsu, N., Mizuta, R., Kondo, N., Takata, T., Kitamatsu, M., Igawa, K., Fujimura, A., Otani, Y., Shirakawa, M., Shigeyasu, K., Teraishi, F., Togashi, Y., Suzuki, M., Fujiwara, T., & Michiue, H. (2024). Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐ NIT ). Cancer Science, 115(10), 3231-3247. https://doi.org/10.1111/cas.16298

Vancouver

Fujimoto T, Yamasaki O, Kanehira N, Matsushita H, Sakurai Y, Kenmotsu N, et al. Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐ NIT ). Cancer Science. 2024;115(10):3231-3247. doi:10.1111/cas.16298

BibTeX
@article{Fujimoto2024,
  author = {Fujimoto, Takuya and Yamasaki, Osamu and Kanehira, Noriyuki and Matsushita, Hirokazu and Sakurai, Yoshinori and Kenmotsu, Naoya and Mizuta, Ryo and Kondo, Natsuko and Takata, Takushi and Kitamatsu, Mizuki and Igawa, Kazuyo and Fujimura, Atsushi and Otani, Yoshihiro and Shirakawa, Makoto and Shigeyasu, Kunitoshi and Teraishi, Fuminori and Togashi, Yosuke and Suzuki, Minoru and Fujiwara, Toshiyoshi and Michiue, Hiroyuki},
  title = {Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐ NIT )},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {10},
  pages = {3231--3247},
  doi = {10.1111/cas.16298}
}
Kostenlos starten →